Outlook, which received regulatory approval earlier this year in the European Union and the U.K. for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet ...
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- ...
Verywell Health on MSN5d
7 Common Eye Diseases and How They Are TreatedEye diseases like glaucoma, cataracts, and conjunctivitis are some of the more common types. Find eye disease awareness and ...
Lorati Company Limited has introduced a groundbreaking advancement in the treatment of age-related macular degeneration (AMD), including both dry and wet forms, with its nano-grade eye drops. Mr.
The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...
Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...
In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...
A retrospective review of home-based optical coherence tomography (OCT) monitoring for neovascular age-related macular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback